chr16-8811152-C-T
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_000303.3(PMM2):c.421C>T(p.Arg141Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000292 in 1,573,038 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R141H) has been classified as Pathogenic.
Frequency
Consequence
NM_000303.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PMM2 | NM_000303.3 | c.421C>T | p.Arg141Cys | missense_variant | 5/8 | ENST00000268261.9 | NP_000294.1 | |
PMM2 | XM_047434215.1 | c.172C>T | p.Arg58Cys | missense_variant | 3/6 | XP_047290171.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PMM2 | ENST00000268261.9 | c.421C>T | p.Arg141Cys | missense_variant | 5/8 | 1 | NM_000303.3 | ENSP00000268261 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152162Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.0000207 AC: 4AN: 193568Hom.: 0 AF XY: 0.0000193 AC XY: 2AN XY: 103370
GnomAD4 exome AF: 0.0000289 AC: 41AN: 1420876Hom.: 0 Cov.: 31 AF XY: 0.0000256 AC XY: 18AN XY: 703576
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152162Hom.: 0 Cov.: 34 AF XY: 0.0000269 AC XY: 2AN XY: 74320
ClinVar
Submissions by phenotype
PMM2-congenital disorder of glycosylation Pathogenic:6
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Feb 17, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 14, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 06, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 141 of the PMM2 protein (p.Arg141Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with congenital disorder of glycosylation (PMID: 15844218). ClinVar contains an entry for this variant (Variation ID: 550780). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PMM2 protein function. Experimental studies have shown that this missense change affects PMM2 function (PMID: 15844218). This variant disrupts the p.Arg141 amino acid residue in PMM2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9497260, 11517108, 19357119, 21541725, 25355454). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 21, 2020 | Variant summary: PMM2 c.421C>T (p.Arg141Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.1e-05 in 193568 control chromosomes (gnomAD). c.421C>T has been reported in the literature in a family affected with Congenital Disorder of Glycosylation Type 1a (LeBizec_2005). These data do not allow any conclusion about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity in an E. coli-based expression system (LeBizec_2005). Two other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories cited the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 23, 2023 | - - |
PMM2-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 24, 2024 | The PMM2 c.421C>T variant is predicted to result in the amino acid substitution p.Arg141Cys. This variant along with a second variant in this gene has been reported in one family with congenital disorder of glycosylation 1a (Le Bizec et al. 2005. PubMed ID: 15844218). A different variant affecting the same amino acid (p.Arg141His) has been reported to be the most common disease allele for carbohydrate-deficient-glycoprotein syndrome type 1 (Matthijs et al. 1998. PubMed ID: 9497260). This variant is reported in 0.0048% of alleles in individuals of African descent in gnomAD. In ClinVar, this variant has been reported as likely pathogenic/pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/550780/). This variant is interpreted as likely pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 14, 2022 | Reported in a patient with Congenital disorder of Glycosylation type Ia who also harbored an additional missense variant in the PMM2 gene (Le Bizec et al., 2005); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate that this variant has a damaging effect on the function of the PMM2 protein (Le Bizec et al., 2005); This variant is associated with the following publications: (PMID: 11058895, 26206375, 16540464, 15844218) - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 21, 2022 | The c.421C>T (p.R141C) alteration is located in exon 5 (coding exon 5) of the PMM2 gene. This alteration results from a C to T substitution at nucleotide position 421, causing the arginine (R) at amino acid position 141 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at